Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice by Seigne, Christelle et al.
RESEARCH ARTICLE Open Access
Characterisation of prostate cancer lesions
in heterozygous Men1 mutant mice
Christelle Seigne
1, Sandra Fontanière
1,2, Christine Carreira
1,2, Jieli Lu
1,7, Wei-Ming Tong
2,3, Bernard Fontanière
4,
Zhao-Qi Wang
2,5, Chang Xian Zhang
1,7*, Lucien Frappart
6
Abstract
Background: Mutations of the MEN1 gene predispose to multiple endocrine neoplasia type 1 (MEN1) syndrome.
Our group and others have shown that Men1 disruption in mice recapitulates MEN1 pathology. Intriguingly, rare
lesions in hormone-dependent tissues, such as prostate and mammary glands, were also observed in the Men1
mutant mice.
Methods: To study the occurrence of prostate lesions, we followed a male mouse cohort of 47 Men1
+/- mice and
23 age-matched control littermates, starting at 18 months of age, and analysed the prostate glands from the
cohort.
Results: Six Men1
+/- mice (12.8%) developed prostate cancer, including two adenocarcinomas and four in situ
carcinomas, while none of the control mice developed cancerous lesions. The expression of menin encoded by the
Men1 gene was found to be drastically reduced in all carcinomas, and partial LOH of the wild-type Men1 allele was
detected in three of the five analysed lesions. Using immunostaining for the androgen receptor and p63, a basal
epithelial cell marker, we demonstrated that the menin-negative prostate cancer cells did not display p63
expression and that the androgen receptor was expressed but more heterogeneous in these lesions. Furthermore,
our data showed that the expression of the cyclin-dependent kinase inhibitor CDKN1B (p27), a Men1 target gene
known to be inactivated during prostate cell tumorigenesis, was notably decreased in the prostate cancers that
developed in the mutant mice.
Conclusion: Our work suggests the possible involvement of Men1 inactivation in the tumorigenesis of the prostate
gland.
Background
Mutations of the MEN1 gene predispose patients to
multiple endocrine neoplasia type 1 (MEN1), charac-
terised by the occurrence of multiple endocrine tumours
affecting mainly the parathyroid glands, the endocrine
pancreas and the anterior pituitary [1]. Shortly after the
identification of the MEN1 gene, several nonendocrine
tumours were also reported in MEN1 patients, such as
lipoma and angioma [2,3]. The MEN1 gene encodes a
primarily nuclear-localised protein named menin that
has been shown to interact with a variety of other pro-
teins [4]. In particular, its interaction with several tran-
scriptional factors and co-factors suggests that menin
may act as an adaptor protein involved in the regulation
of gene expression. However, little is known about the
in vivo physiological function of menin and the in vivo
importance of the aforementioned protein-protein inter-
actions, especially in the endocrine cells commonly
affected in MEN1 disease.
By disrupting Men1 in mice, we and others have pre-
viously shown that, while homozygous Men1 mutant
mice die embryonically, heterozygous Men1 mutant
mice largely recapitulate the major endocrine lesions
seen in MEN1 pathology [5-8]. However, these mice
develop several types of neoplastic lesions that are rarely
seen in MEN1 patients, such as high frequency sex-cord
stromal cell tumours in 88% of aged male mice and 50%
of female mice [6,8]. Intriguingly, we have found three
cases (3/36, 8,3%) of breast cancer in heterozygous
Men1 female mice [6], and Crabtree et al.d o c u m e n t e d
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zygous Men1 mouse cohort [7]. Consistent with these
observations, Dreijerink et al. have shown that menin
interacts physically, in a ligand-dependent manner, with
several nuclear receptors, such as the oestrogen receptor
(ER) [9] and peroxisome proliferator activated receptor
gamma (PPARg) [10], and that menin acts as a coactiva-
tor of nuclear receptor mediated transcription. These
studies raise the question of whether Men1 inactivation
could predispose to the development of hormone-
d e p e n d e n tt u m o u r s .T oi n v e s tigate the possible link
between the development of prostate cancer and Men1
disruption, we followed a cohort of aged male hetero-
zygous Men1 mutant mice. Several cases of prostate
cancer were found in this group, whereas no cases were
seen in control animals. Interestingly, the expression of
menin was inactivated in these prostate cancers, and
partial LOH (loss of heterozygosity) of the wild-type
Men1 allele was found. Gene expression analyses further
revealed that the expression of CDKN1B (cyclin-depen-
dent kinase inhibitor 1B, also called p27), a known
menin target gene [11,12], was markedly reduced in the
analysed prostatic carcinomas.
Methods
Men1 mutant mice
Men1
+/- mice carrying an inactivated Men1 allele were
generated as previously described [5]. These mutant
mice with mixed C57BL6/129-Sv genetic background
give rise to multiple endocrine lesions mimicking the
human MEN1 tumour spectra as previously described
[6]. Littermate Men1
+/- and Men1
+/+ male mice were
used for the analyses to limit the bias possibly originat-
ing from the mixed genetic background. All animal
experiments were conducted in accordance with
accepted standards of animal care and were approved
by the International Agency for Research on Cancer’s
Animal Care and Use Committee.
Genotyping and LOH analysis
PCR genotyping analyses were performed to determine
t h ep r e s e n c eo ft h ew i l d - t y p ea n dm u t a n tMen1 alleles
as previously described [6]. For LOH analysis, menin-
immunostained prostate sections were used to locate
menin-negative lesions. Genomic DNA was then
extracted from corresponding microdissected paraffin-
embedded sections as previously described [6]. The
wild-type (+) and mutant (-) Men1 alleles were first
amplified from 1 μg of genomic DNA by PCR, carried
out as described for genotyping [6], using the following
three primers: 2f0, 5-CTTACCTCTTCTCATGTCTG;
2r0, 5-CTCAGTACATTGCACGGAGA; and tk1.1,
5-GCGTTGCGTGGGGTCAG. Southern blots were
then performed by standard methods on these PCR
products using a probe for each Men1 allele generated
by amplification of genomic DNA from a Men1 hetero-
zygous mutant mouse with the PCR described above.
Autoradiography films were scanned with the EC3
imaging system (UVP Bioimaging Systems), and the
intensity of each band was quantified with Visionworks
LS software. The ratio between the intensities of the +
and - Men1 alleles (+/- ratio) was then calculated to
evaluate the loss of the wild-type Men1 allele.
Histopathological analyses
Prostate glands and adjacent tissues were collected from
wild-type and heterozygous Men1 mutant mice, fixed in
4% buffered formalin for at least 24 h at room tempera-
ture, and processed for paraffin-embedding, sectioning
(3 μm) and haematoxylin and eosin staining. Histo-
pathological examination of prostate samples was
performed independently by three pathologists (B Fonta-
nière, L Frappart and WM Tong), including a mouse
model specialist (WM Tong), on a blinded basis accord-
ing to the criteria recommended by the consensus
report from the Bar Harbor meeting of the mouse mod-
els of human cancer consortium (MMHCC) prostate
pathology committee [13]. The WHO Classification of
Tumours of the Urinary System and Male Genital
Organs (2004) was also used. More than 3 prostate sec-
tions were examined for each mouse and lobe origin
was distinguished during the scoring process. The final
diagnosis was then reached by a common decision.
Immunostaining analysis
Immunohistochemical (IHC) staining was performed on
prostate serial sections as previously described [6], using
antibodies against menin (BL342, Bethyl Laboratories,
Montgomery, TX, USA, 1:6000), androgen receptor
(C-19, Santa Cruz Biotech, Santa Cruz, CA, USA,
1:4000) and CDKN1B (F-8, Santa Cruz Biotech, 1:2000).
In all these analyses, a control without primary antibody
was systematically included to rule out non-specific
staining due to secondary antibody reactivity (data not
shown). Immunofluorescence (IF) double staining was
performed on paraffin-embedded prostate sections.
Briefly, after endogenous peroxidase inactivation, antigen
retrieval and antibody diluent treatment (DAKO, Capin-
teria, CA, USA), sections were incubated overnight with
primary antibody against menin (BL342, 1:6000). After
secondary antibody incubation (anti-rabbit, Vector Lab,
1:200), the signal was amplified using the ABC Vectas-
tain elite kit (Vector Lab) and the TSA Cyanine 3 kit
(PerkinElmer, Waltham, MA, USA, 1/100). Slides were
s a t u r a t e do n c em o r ei nD A K Oa n t i b o d yd i l u e n ta n d
then incubated overnight with primary antibodies
against p63 (Ab-1, Oncogene Research products, San
Diego, CA, USA, 1:2000) or CDKN1B (Santa Cruz
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antibody (anti-mouse, Vector Lab, 1:200). The signals
were revealed by the ABC kit and TSA Cyanine 5 (Per-
kinElmer, 1/100). Slides were mounted in IF Vectashield
DAPI-containing mounting medium (Vector Lab), and
the immunofluorescence signal was visualised with a
confocal microscope (LEICA TCS SP2).
Results
A proportion of aged heterozygous Men1 mutant mice
develop prostate cancer
To determine the effect of Men1 inactivation on pros-
tate cancer development in mice, we followed a cohort
of 47 male mutant mice (Men1
+/-)a n d2 3w i l d - t y p e
(Men1
+/+) age-matched littermate mice from 18 to 26
months of age, based on a previous study that showed
no prostate cancer in younger mice [6].
Histopathologic analysis of the prostate glands from
these mice was performed in accordance with the cri-
teria defined by the MMHCC [13]. A comparison
between age-matched Men1 wild-type and mutant mice
revealed notable histological differences, showing a
marked increase in cancer incidence in Men1
+/- pros-
tates (Table 1) and a significantly decreased proportion
of mutant mice with normal prostate histology. The
results showed 30.4% of Men1 wild-type prostates with
normal histology while only 6.4% of prostate glands
from mutant mice were free of lesions (p = 0.0266, Fish-
er’s two-tailed exact test). Normal prostate tissue pre-
sented as a single layer of secretory epithelial cells lined
by a well-defined outer basal cell layer, with uniform
small nuclei containing inconspicuous or small nucleoli.
The epithelial hyperplasia diagnosed in this study
appeared as increased numbers of epithelial cells, with
or without atypia, associated with increased gland size.
The intraluminal proliferation of markedly atypical
epithelial cells, with tufted, cribriform or micropapillary
growth pattern, was recognised histologically as mouse
prostatic intraepithelial neoplasia (mPIN) (Figure 1B).
Carcinomas were characterised by frequent mitotic
figures, apoptotic debris and cytologic atypia, such as
amphophilic cytoplasm, increased nuclear-cytoplasmic
ratio, hyperchromasia, prominent and multiple nucleoli,
chromatin clumping and pleomorphism (Figure 1C, D, E).
Hyperplastic and mPIN lesions, mainly presenting in
the lateral and anterior lobes of prostatic glands, were
observed with similar frequency in mutant and wild-
type aged mice (Table 1, 43.5% in Men1
+/+ versus 46.8%
in Men1
+/- mice for hyperplasia and 26.1% in Men1
+/+
versus 34% in Men1
+/- mice for mPIN), and a few of
them were also found in dorsal and ventral lobes. How-
ever, the incidence of mPIN in mutant mice was under-
estimated because four mPIN lesions observed in
mutant mice with in situ carcinomas were not counted,
since only the most severe lesion was taken into account
for each mouse. The real incidence of mPIN in Men1
+/-
mice should thus be 42.5%. The occurrence of both
hyperplasia and mPIN lesions has already been reported
in some wild-type mouse strains [14].
More importantly, our analysis revealed that, of 47
heterozygous Men1 mutant mice, six developed prostate
cancers (12.8%). No prostate carcinoma was ever found
in age-matched Men1
+/+ littermates (0/23). Among the
prostate cancers observed in Men1
+/- mice, four were
identified as in situ prostate carcinomas presenting as
microscopic lesions (one in dorsal prostate, shown in
Figure 1C, two in lateral prostate, and one in anterior
prostate), one papillary adenocarcinoma in the anterior
prostate (Figure 1D) and one differentiated invasive ade-
nocarcinoma in the lateral prostate (Figure 1E, F), with
the latter two visible on gross examination. Invasive tis-
sue was found in epithelial areas lacking an intact basal
cell layer, with cancerous cells invading the surrounding
stroma (Figure 1F). Among the observed prostatic
lesions, none displayed histopathological features typical
of neuroendocrine differentiation (solid or sheet-like
proliferation of closely spaced oval or spindle cells with
scant cytoplasm and hyperchromatic nuclei, with areas
of rosette formation) [13].
Taken together, our data revealed the development
of prostate carcinomas in a small proportion of aged
heterozygous Men1 mutant mice.
Menin expression is inactivated in cancerous lesions
mainly through LOH
Menin expression was assessed in the different prostatic
lobes from Men1 wild-type mice using either IHC for
menin or double IF with antibodies against menin and
p63, a basal epithelial cell marker. IHC analysis revealed
that menin expression, which is mainly nuclear but can
also be detected in the cytoplasm, was found in all pro-
static lobes from Men1 wild-type mice in both luminal
and basal prostatic epithelial cells (Figure 2A) but not in
interstitial cells. Double IF staining of menin and p63
Table 1 Morphologic alterations in the prostate glands of
male heterozygous Men1 mice
Type of pathology Men1
+/+ Men1
+/-
Normal prostate 7/23 (30.4%)
a 3/47 (6.4%)*
Hyperplasia 10/23 (43.5%) 22/47 (46.8%)
mPIN 6/23 (26.1%) 16/47 (34%)
Carcinoma 0/23 (0%) 6/47 (12.8%)
Men1
+/+ and Men1
+/- male mice were monitored for cancer development and
examined by histology between 18 and 26 months.
a Number of mice of each
histological category over the total number of the mice examined. The
percentage of mice in each histological category is shown in parentheses. For
each mouse, only the most severe type of lesion was taken into account. For
this reason, mPINs observed in four mice having carcinoma lesions were not
counted in this table. * p = 0.0266 (Fisher’s exact test).
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association between the occurrence of prostatic lesions
in heterozygous Men1 mice and inactivation of the
Men1 gene, we examined menin expression by IHC in
the corresponding lesions. We found that menin expres-
sion was readily detectable by IHC in all four tested
mPIN lesions from WT mice (data not shown), but
clearly reduced in two of four mPIN lesions from
mutant mice (Figure 2B, F). The data suggest that,
although a large proportion of mPINs observed in
mutant mice occur independently of Men1 inactivation,
a st h o s es e e ni nw i l d - t y p em i c e ,s o m em a ys t i l lb e
related to menin loss. In contrast to mPIN lesions, no
menin expression was detectable in the six prostate can-
cers found in Men1
+/- mice (Figure 2C-E and 2G-I),
suggesting that prostate cancer in these mice was likely
caused by menin inactivation, rather than the secondary
effects of MEN1 pathology, such as gene expression
and/or hormone disturbance in endocrine tissues. In
two of the prostate cancers shown in Figure 2 (panels
D, H and E, I), a small number of cells remain positive
for menin expression. We reasoned that these cells were
in fact normal basal epithelial cells that remained in
cancer lesions, which was confirmed by further analyses
(see below).
To further study the related mechanisms leading to
menin inactivation, we tested the presence of LOH in
mPIN from Men1
+/- mice displaying reduced menin
expression and in menin-negative carcinoma lesions
detected by IHC analysis. To this end, the tested tissues
were scraped from the corresponding paraffin-embedded
slides, and genomic DNA was extracted from each
lesion. Genotyping analysis demonstrated that partial
LOH was indeed found in three of five analysed precan-
cerous and cancerous lesions (Figure 2J). The quantifica-
tion of amplified products corresponding to Men1
+ and
Men1
- alleles from the tail of a Men1
+/- mouse was used
as a control, and an identical intensity of both alleles
was achieved, thus giving a +/- ratio equal to one. The
intensity of the wild-type allele (+), but not the mutant
allele (-), was reduced in two mPINs (PIN1 and 2, both
showing reduction of menin expression by IHC analysis)
and in an adenocarcinoma lesion (ADC) from Men1
+/-
mice, as demonstrated by the lower +/- ratios for these
lesions when compared with the control (Figure 2J). We
assume that the residual wild-type allele, amplified from
the tested lesions, was derived mainly from the remain-
ing normal basal cells within the lesions, which were
shown to retain menin expression. The result suggests
that LOH of the remaining wild-type Men1 allele may
be one of the mechanisms leading to menin inactivation
in the prostate cancers developed in this model,
although we cannot exclude that other mechanisms may
also be involved.
Figure 1 Precancerous and cancerous lesions are detected in aged male heterozygous Men1 mutant mice.H a e m a t o x y l i na n de o s i n
staining of a normal lateral prostate lobe from a 24-month-old Men1
+/+ mouse (A) and precancerous or cancerous lesions observed in prostate
glands from heterozygous Men1 mutant mice (B-F). (B) mPIN found in the anterior prostate with a signet ring variant: cytoplasmic vacuoles
displacing the cell nuclei (21-month-old mouse). (C) In situ carcinoma in the dorsal prostate (26-month-old mouse). (D) Adenocarcinoma in the
anterior prostate with branching and papillary infolding (23-month-old mouse). (E) Differentiated invasive adenocarcinoma in the lateral prostate
(in situ component) from a 23-month-old mouse. (F) Invasive component of the same lesion as in (E) showing invasion to the prostatic
connective tissue. Insets show a magnified view of a part of the prostate glands. Scale bars, 50 μm.
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mutant mice do not express p63 and display
heterogeneous AR expression
Although a loss of menin expression and a partial LOH
were found in some mPINs from Men1 mutant mice,
these occurred at similar frequencies in wild-type and
mutant mice. The present study therefore focused on
the analysis of the prostate cancers arising in Men1
mutant mice. To further characterise the observed can-
cer lesions, expression of the basal epithelial marker p63
was analysed using double IF staining, since the
diagnosis of cancerous lesions can often be based on the
disruption of the basal cell layer indicated by the
absence or greatly reduced number of p63-positive basal
cells [15]. Menin-negative cancerous cells were nega-
tively stained with basal cell marker p63 (Figure 3E-H).
In addition, normal p63-positive basal cells, which
retained menin expression, were greatly reduced in
number and scattered in the cancerous lesions, showing
a disruption of the basal cell layer (Figure 3H, white
a r r o w h e a d ) .T h ed a t aw e r et h u sc o n s i s t e n tw i t ho u r
histopathologic findings and indicated that menin
Figure 2 Menin expression is inactivated in prostate cancers from Men1
+/- mice. Microscopic images of prostate glands from Men1
+/+ (A)
and Men1
+/- mice (B-I) subjected to menin detection by IHC. Menin is widely expressed in the nuclei of prostate epithelial cells in the lateral
(LP), dorsal (DP), ventral (VP) and anterior (AP) prostate from a 21-month-old Men1
+/+ mouse (A), but is completely inactivated in two of four
tested mPINs and in all six prostatic cancerous lesions in Men1
+/- mice. Four representative types of lesions are shown: mPIN from a 21-month-
old Men1
+/- mouse (B, F), an in situ prostate carcinoma from a 26-month-old mouse (C, G), a well-differentiated adenocarcinoma from a 23-
month-old mouse (D, H) and a papillary adenocarcinoma from a 23-month-old mouse (E, I). Panels F-I are two-fold magnifications of the upper
panels (B-E). Insets show an amplified view of a part of the prostate glands. Scale bars, 50 μm. (J) Representative results from two independent
LOH analyses of prostatic lesions in Men1
+/- mice. Semi-quantitative amplification of Men1 wild-type (+) and mutant (-) alleles with PCR was
performed on DNA samples extracted from microdissected paraffin-embedded sections from Men1
+/+ normal prostate (WT) and prostate lesions
from Men1
+/- mice, including two mPIN (PIN1 and PIN2) and one adenocarcinoma (ADC). Tail DNA from wild-type (+/+) and heterozygous (+/-)
Men1 mice were used as controls. The intensity of both alleles (+ and -) was quantified and used to calculate the +/- ratio, which was compared
with the +/- ratio obtained from the controls.
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what we had speculated on the basis of the results
obtained by menin IHC.
Prostatic cells express the androgen receptor (AR) and
respond to the androgen pathway that regulates prostate
growth, apoptosis and differentiation. Nearly 70% of
clinical prostate cancer cases are AR positive. It is gen-
erally considered that AR expression in prostate cancer
cells reflects not only the differentiation status of the
cells, but also their sensitivity to anti-AR treatment. We
therefore evaluated AR expression using IHC in differ-
ent prostate tissue samples. Normal prostate tissue from
Men1
+/+ mice showed strong AR nuclear staining in
b o t hl u m i n a la n db a s a le p i t h e l i a lc e l l s ,a sw e l la si n
many stromal cells (Figure 3I, L), as previously described
in the literature [16-18]. AR was clearly expressed in an
in situ carcinoma (Figure 3J, M) and an adenocarcinoma
(Figure 3K, N) and showed a heterogeneous expression
Figure 3 Prostate cancers from Men1
+/- mice do not express p63 and display heterogeneous AR expression. (A-H) Double IF staining
using antibodies against menin (red) and p63 (green) performed on a normal prostate from a 24-month-old Men1
+/+ mouse (A-D, n = 2) and
an adenocarcinoma found in a Men1
+/- mouse of the same age (E-H, n = 2). DAPI stains cell nuclei. Note that normal p63-expressing basal cells
scattered within the lesion remain menin-positive (shown by white arrowheads). Boxed areas are magnified in the insets. Scale bars, 50 μm. (I-N)
IHC using antibody against AR was performed on prostate tissues from Men1
+/+ (I, L, n = 4) and Men1
+/- (J, M and K, N, n = 4) mice. AR
expression is present but more heterogeneous in an in situ prostate carcinoma (J, M, 26-month-old mouse) and an adenocarcinoma (K, N, 23-
month-old mouse) from Men1
+/- mice, with some cells showing greatly reduced AR expression compared to the control. Panels L-N are two-fold
magnifications of the upper panels (I-K). Insets show an amplified view of a part of the prostate glands. (O) Prostatic epithelial nuclei showing
absent or very low AR expression were counted in six random microscopic fields in normal prostate glands from Men1
+/+ mice (n = 3) and
carcinomas observed in Men1
+/- prostate glands (n = 4), stained with an anti-AR antibody. The results are expressed as a percentage of total
prostatic epithelial cells (250 nuclei counts). Values are means ± standard error of the mean. *** Significant difference from normal Men1
+/+
prostate with a two-tailed Student’s t-test (P < 0.0001).
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control prostate (Figure 3I, L), with some cells showing
absent or very low AR staining. Quantitation of epithe-
lial cell nuclei displaying either no AR expression or
very low staining revealed a significant increase in the
number of cells with altered AR expression in prostate
carcinomas from Men1 mutant mice compared with
normal Men1
+/+ prostate glands (Figure 3O).
The data demonstrated the disruption of the basal cell
layer in these lesions and suggested a possible associa-
tion between menin inactivation and the deregulation of
AR expression.
The reduced expression of CDKN1B was evidenced in
prostatic carcinomas
CDKN1B, an inhibitor of cyclin-dependent kinases, is a
transcriptional target of the menin protein [11,12]. The
involvement of its downregulation in the tumorigenesis
of prostate cells has also been well documented in dif-
ferent mouse models and in prostate cancer patients
[19,20]. We therefore analysed the expression of
CDKN1B using IHC in serial sections of prostate carci-
nomas from Men1
+/- mice. Strong, predominantly
nuclear CDKN1B expression was detected in virtually all
luminal and basal Men1
+/+ prostate cells (Figure 4A, D),
consistent with previous reports [21,22]. CDKN1B
nuclear expression was clearly reduced in an in situ car-
cinoma (Figure 4B, E) and almost absent in an adeno-
carcinoma (Figure 4C, F) from Men1
+/- mice.
Furthermore, double IF staining with menin and
CDKN1B antibodies showed that the reduced expression
of CDKN1B in prostate carcinomas correlated well with
the loss of menin expression (Figure 4K-N), indicating
that CDKN1B expression is indeed down-regulated in
menin-negative prostatic cells.
Discussion
In the current study, analysis of a cohort of aged male
Men1
+/- mice showed a significant reduction in the
number of mutant mice with normal prostate glands
d u et ot h eo c c u r r e n c eo fp r o s t a t el e s i o n si nt h e s em i c e .
Interestingly, six mutant mice developed prostate can-
cer, which was not observed in the age-matched wild-
type littermates. The prostate lesions found in heterozy-
gous Men1 mutant mice were characterised by a slow
cancer development process, which ranged from in situ
carcinoma to invasive adenocarcinoma. This cancer
development pattern in aged male heterozygous Men1
mice is similar to other non SV40-TAg GEM prostate
cancer models, likely reflecting the relative late and slow
features of prostate cancer development in men.
Although one prostate cancer case was previously docu-
mented in an independent heterozygous Men1 mutant
mouse cohort [7], to our knowledge, the present study
is the first systematic evaluation and characterisation of
prostate cancer related to the inactivation of the Men1
gene.
Importantly, the menin protein was undetectable in
cancerous cells, and partialL O Hw a sf o u n di nt h r e eo f
five pre-and/or cancerous lesions from Men1
+/- mice.
Menin loss in these mutant mice may indicate a close
relationship between Men1 inactivation and the develop-
ment of prostate cancer, suggesting that the Men1 gene
may possess oncosuppressive activity and be involved in
the control of cell proliferation in prostate epithelial
cells. However, we noticed that the occurrence of pros-
tate cancer in these mice can be seen only in aged mice
with a low frequency, implying that Men1 inactivation
may confer a relatively minor predisposition to prostate
cancer development compared with the endocrine tis-
sues affected in MEN1 pathology and that other factors
may be involved in the development of this pathology.
Interestingly, these results are similar to the findings
with mice carrying either one mutated Pten or the
Nkx3.1 allele. Male heterozygous Pten mice develop
mPIN at ages older than 9 months [19], whereas Nxk3.1
mutant mice show only hyperplastic or dysplastic pro-
static epithelium [23]. However, the double mutant Pten
+/-: Nxk3.1
+/- mice display high grade PIN/early carci-
noma lesions at a high frequency [24,25]. Both genes
have been found either mutated or down-regulated in
human prostate cancer [19,26]. The results of the pre-
sent study suggest that the Men1 gene could be among
the rare known tumour suppressors whose disruption
leads to the development of prostate cancer in mice,
albeit at low incidence and with a slow progression rate.
Intriguingly, a recent study reported that gain at the
MEN1 locus was detected in a substantial proportion of
human metastatic prostate cancers, and a trend toward
increased menin expression in human prostate cancers
and metastatic tissues was suggested by a meta-analysis
of MEN1 expression data in prostate cancer [27]. Simi-
larly, Imachi et al. reported that menin expression in
breast cancers could be used as a prognostic factor of
worse outcome [28]. Knowing the multifaceted role
played by the MEN1 gene, menin may play an onco-
genic role under certain circumstances in these tissues,
particularly in recurring and aggressive cancers, in simi-
larity to the well-known dual role played by the TGF-b
pathway, whose several effectors are the protein partners
of menin, in the process of tumourigenesis. However,
further clinical studies are needed to validate these
observations, as mentioned by the authors.
Our results suggest that the study of the potential link
between menin and AR expression or activity in pro-
static cells would be of great interest, as the latter is
deregulated in the prostate cancers found in Men1
mutant mice. Generally considered a co-regulator of
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with several nuclear receptors, such as ERa [9] and
PPARg [10], playing the role of a transcriptional coacti-
vator via its LXXLL motif. Although a physical interac-
tion between menin and AR has not been reported yet,
the existence of cross-talk between menin and the AR
pathways is possible. Indeed, menin and AR share com-
mon partners like Smad3, a downstream effector of the
TGF-b signalling pathway, and b-catenin, an effector of
WNT pathway [4,29], but also common target genes
important for cell cycle control, such as CDKN1B and
cyclins D [4,11,12,30,31]. The observation of deregulated
AR expression in the cancerous lesions found in Men1
mutant mice suggests that menin inactivation and sub-
sequent AR deregulation in these cells may lead to the
disturbance of the AR pathway, which could in turn
promote the progression to cancer.
It is worth mentioning that the mutant mice enrolled
in this study developed Leydig cell tumours with high
frequency, which could suggest that the occurrence of
these tumours plays a role in the tumorigenesis of pros-
tate cells. However, the data from previously published
mouse models of Leydig cell tumours did not offer any
evidence supporting this hypothesis, as none reported
Figure 4 Reduced CDKN1B expression in prostate cancers from Men1
+/- mice. (A-F) IHC was performed on paraffin-embedded sections of
prostate tissues from Men1
+/+ (A, D, n = 4) and Men1
+/- (B, E and C, F, n = 4) mice using an antibody against CDKN1B. Note that in the normal
prostate from aged Men1
+/+ mice (26-month-old), CDKN1B is expressed in all prostatic epithelial cells, but not in all stromal cells (A, D). CDKN1B
expression is reduced in an in situ carcinoma (B, E, 26-month-old mouse) and an adenocarcinoma (C, F, 23-month-old mouse) from Men1
+/- mice
when compared with the wild-type prostate. Panels D-F are two-fold magnifications of the upper panels (A-C). Insets show an amplified view of
a part of the prostate glands. (G-N) Menin (red) and CDKN1B (green) expressions examined by double IF staining in prostate glands from a 21-
month-old Men1 wild-type mouse (G-J) and an adenocarcinoma from a 23-month-old Men1
+/- mouse (K-N). DAPI stains cell nuclei. Note that
menin and CDKN1B expressions are co-localised in normal prostate epithelium, whereas both disappear in the cancerous lesions. Arrowheads
show that basal cells remain both menin and CDKN1B positive in cancerous lesions. Boxed areas are magnified in the insets. Scale bars, 50 μm.
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Page 8 of 10prostate lesions [32-36]. Furthermore, AR signalling
seems to play a growth suppressing function in the
initial stage of tumour development [30]. Nevertheless,
it will be interesting in the future to investigate the pos-
sible interplay between the development of Leydig cell
tumours and the occurrence of prostate cancer.
Prior studies have proposed that the growth inhibition
function of AR signalling in normal prostatic luminal
cells is mediated by its induction of CDKN1B expression
[30]. This indeed correlates with the downregulation of
CDKN1B observed in prostate carcinomas developed in
our Men1 mutant mice. CDKN1B, which is closely
related to the tumorigenesis of prostate cancers as
described above, is among the transcriptional targets of
menin. The mouse models with CDKN1B disruption in
combination with other genetic factors, such as Pten
and Nkx3.1, have been shown to develop a range of
prostate cancers, although CDKN1B inactivation alone
displays no obvious neoplastic prostate lesions [19,25].
The downregulation of CDKN1B found in prostate
lesions in Men1 mutant mice suggests the in vivo
importance of CDKN1B inactivation in the tumorigen-
esis related to Men1 inactivation, similar to observations
in other mouse Men1 tumour models [12,37-39].
Furthermore, it would be interesting to clarify the possi-
ble relation between menin and other factors involved
in CDKN1B regulation in the prostate, such as Pten and
Nkx3.1, in the future.
Conclusion
The presented data suggest the possible involvement of
Men1 inactivation in the tumorigenesis of prostatic cells
in mice. Recent extensive genetic studies highlighted the
difficulties in identifying genes involved in the tumori-
genesis of prostate cells [40], indicating that prostate
cancer could be a genetically complex disease with mul-
tiple predisposing factors affecting initiation, progres-
sion, and outcome of the disease. It would thus be
interesting to investigate the eventual oncosuppressive
role of the Men1 gene in prostatic cells in humans in
the future. The current study also suggests that both
altered AR and CDKN1B expression may be among the
factors participating in or facilitating the tumorigenesis
of prostatic cells due to Men1 inactivation.
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